Measuring blood markers to monitor cancer treatment response
Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
This study is testing if certain blood markers can help doctors better understand how well cancer treatments are working for patients and predict their chances of recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stanford University Academic / other |
| Locations | 1 site (Stanford, California) |
| Trial ID | NCT00349830 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect and analyze blood serum from cancer patients and those suspected of having cancer at Stanford University. By measuring levels of serum proteins and other biomarkers, the study seeks to identify markers that can confirm diagnoses, predict responses to therapy, and assess relapse and survival rates. Blood samples will be collected before, during, and after anti-cancer therapy, and healthy individuals will also be included for comparison. The ultimate goal is to improve diagnostic and treatment strategies for various cancers.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a prior diagnosis of cancer or those suspected of having cancer.
Not a fit: Patients who are not diagnosed with cancer or have a Karnofsky performance status of 70 or below may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate monitoring of cancer treatment responses and better personalized therapy options for patients.
How similar studies have performed: Other studies have shown promise in using serum biomarkers for cancer monitoring, indicating that this approach has potential based on previous findings.
Eligibility criteria
Show full inclusion / exclusion criteria
1. Age \> or = 18; for the samples collected under the NIH grant, no subjects below the age of 20 will be enrolled. 2. Prior diagnosis of cancer or suspected of having cancer 3. Karnofsky performance status of greater than 70 4. Standard pretreatment evaluation 5. Signed Stanford University Human Subjects Committee consent
Where this trial is running
Stanford, California
- Stanford University School of Medicine — Stanford, California, United States (Recruiting)
Study contacts
- Principal investigator: Maximilian Diehn — Stanford University
- Study coordinator: gitrialeligibility@stanford.edu gitrialeligibility@stanford.edu
- Email: gitrialeligibility@stanford.edu
- Phone: 650-498-7757
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.